



 Fundació Doctor Robert
UAB

Review of key concepts in clinical trial methodology

Markku Toivonen, MD, PhD
Scientific Director
NDA Regulatory Science Ltd

June 5, 2016, Barcelona


EURORDIS.ORG




EVIDENCE-BASED MEDICINE

- Care of individual patients is based on evidence
 - From medical research
 - From medical expertise and experience
- Medical research “gold standard”: randomised, controlled trial (RCT)

LEVELS OF EVIDENCE



Confidence



Risk of bias

<http://dx.doi.org/10.1136/ebmed-2016-110401>

Murad et al.

RANDOMISATION

- Study participants are identified based on clear criteria defined in advance (**screening**)
- Participants fulfilling study criteria are assigned to treatment groups randomly
 - Computerised systems
- Neither participants nor study investigators can influence treatment allocation

ADVANTAGES OF RANDOMISATION

Avoids **selection**-based **bias** (systematic error) – possibility that treatment outcome is influenced by selection

Objective: treatment groups within a clinical trial are **balanced** (similar) and only the treatment is different

SHORTCOMINGS?

- Randomisation does not guarantee that the study setting is free from bias, particularly if
 - The participant, the investigator or both know what treatment the individual will receive (open-label study)
- **Studies should be conducted "double-blind" whenever possible**

CONTROLLED

- Control group is a “yardstick” against which efficacy and safety of experimental therapy can be evaluated
- Control treatment (comparator) may be
 - Placebo
 - Standard care + placebo
 - Best supportive care
 - Established therapy – authorised or not authorised, but evidence-based

OUTCOME MEASURES/ENDPOINTS

- Often called **variables**
- **Objective** or **subjective**
 - Objective: impartial – based on observation/physico-chemical measure, low degree of interpretation
 - Subjective – important measure of perceived benefit/harm
- Surrogate endpoints
- Biomarkers

HIERARCHY OF ENDPOINTS

- Defined in advance in protocol
- Primary
 - Most important measure
 - Result defines study success/failure
- Secondary
 - Measure other important aspects of disease
- Tertiary/exploratory
 - Other measures of interest

NON-STANDARD SITUATIONS

- In principle, development of orphan medicinal products is a **standard situation**
- Development may require **non-standard solutions**
 - Historical control group – natural history studies
 - No control group: single arm study
 - Adaptive studies
 - Sequential studies

TO CONCLUDE

Randomised, controlled, blinded studies provide best scientific evidence of benefit and risk

- Not always possible
- Alternative designs to be agreed with authorities in advance